The scientific record on GHRP-2 splits cleanly into what is proven and what is only assumed, and an honest reading holds both at once. The molecule's ability to release growth hormone is well documented, and its single approved use, diagnostic testing under the name pralmorelin in Japan, is real; almost every popular benefit claimed beyond that is extrapolated from growth hormone biology rather than shown directly. GHRP-2 is not FDA-approved for human use, and long-term safety data do not exist.
GHRP-2's growth hormone release and its Japanese diagnostic approval as pralmorelin are documented, while its widely marketed body-composition and anti-aging benefits remain unproven and unsupported by any large long-term trial.
GHRP-2, also called pralmorelin and coded KP-102, is a synthetic hexapeptide in the growth hormone secretagogue class, and its mechanism is the best-characterized part of its science. It binds the GHS-R1a receptor, the same target as the body's own ghrelin, and drives somatotroph cells in the anterior pituitary to release stored growth hormone in a pulsatile pattern closer to normal physiology than injected growth hormone produces.
GHRP-2 is a synthetic hexapeptide that stimulates pituitary growth hormone release by binding the GHS-R1a ghrelin receptor, acting through both GHRH amplification and somatostatin suppression.
The one clinical use with solid documentation is diagnostic, not therapeutic. Marketed in Japan as GHRP Kaken 100 and approved there in 2004, pralmorelin provokes growth hormone release during testing for growth hormone deficiency, and regulatory clearance as a diagnostic in a single country carries no therapeutic endorsement elsewhere.
Under the name pralmorelin, GHRP-2 has been approved in Japan since 2004 as a provocative agent for growth hormone deficiency testing, a one-time monitored diagnostic dose rather than a treatment.
A single dose of GHRP-2 produces a rapid, reproducible growth hormone spike, usually peaking within 15 to 30 minutes, and because most human data come from acute studies this immediate burst is the best-evidenced part of the record. IGF-1, the slower downstream mediator, appears to rise with repeated dosing, but the size and durability of that increase over weeks or months has not been established in large trials.
| Marker | Growth hormone | IGF-1 |
|---|---|---|
| Response timing | Peaks 15 to 30 minutes after a dose | Rises slowly, reflecting sustained exposure |
| Evidence strength | Strong, from acute human studies | Limited, from small short studies |
| Long-term data | Not established beyond short time frames | Magnitude over weeks or months unknown |
A single GHRP-2 dose reliably produces a dose-dependent growth hormone peak within roughly 15 to 30 minutes, while any sustained IGF-1 increase from repeated dosing remains unquantified in large trials.
The GHRP-2 evidence base is real but narrow, and its boundaries matter more than any single finding inside it. Most human studies are small, run for hours to a few weeks, and measure acute hormone levels rather than the durable outcomes people care about, so the literature can support short-term hormonal claims while falling short of any long-term efficacy or safety conclusion.
The GHRP-2 literature supports confident statements only about short-term growth hormone and IGF-1 dynamics, and cannot substantiate claims about long-term changes in body composition, strength, or safety.
The missing trials are less an oversight than a predictable outcome of how drug research gets funded. Multi-year efficacy and safety studies cost enormous sums that sponsors recoup through exclusive commercial rights, and GHRP-2 is an old, off-patent peptide with a narrow diagnostic identity, so no company has a financial reason to run pivotal therapeutic trials on it.
GHRP-2 lacks the patent protection that funds multi-year trials and holds only a single-market diagnostic approval, so the long-term efficacy and safety questions most relevant to non-diagnostic use are the least likely to ever be tested.
The honest split here is between what studies measured and what is inferred by chaining assumptions together. A narrow set of effects is directly demonstrated in humans, while the popular benefits, fat loss, muscle gain, faster recovery, deeper sleep, and anti-aging, rest on the plausible but unproven logic that raising growth hormone must deliver whatever growth hormone influences.
| Category | Demonstrated in humans | Extrapolated only |
|---|---|---|
| Hormonal | Growth hormone pulse, modest prolactin and cortisol rise | Durable IGF-1-driven tissue benefits |
| Body composition | None directly shown | Meaningful fat loss and muscle gain |
| Recovery and aging | None directly shown | Faster injury repair, deeper sleep, anti-aging |
GHRP-2's growth hormone pulse and modest rises in prolactin and cortisol are directly documented, while claimed fat loss, muscle gain, recovery, and anti-aging benefits remain untested extrapolations from growth hormone biology.
Because GHRP-2 acts on the same receptor as ghrelin, the hunger hormone, appetite stimulation is one of its genuinely observed effects rather than an extrapolated one. Activation of GHS-R1a promotes food intake, which is why ghrelin-receptor agonists as a class have drawn research interest for wasting conditions such as cancer cachexia.
Appetite stimulation is a directly observed effect of GHRP-2 through GHS-R1a activation, though it is milder than GHRP-6's and secondary to the compound's primary growth hormone release.
The safety record is reassuring for short-term controlled use and nearly silent about anything longer. Reported effects in diagnostic and short studies are mild and transient, but the trials needed to catch slower-developing problems were never run, so long-term safety is genuinely unknown.
GHRP-2's reported adverse effects in short-term studies are mild and transient, but its long-term safety is essentially unknown because the necessary trials were never conducted, and unregulated products add purity and dosing hazards beyond the molecule itself.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
